BioXcel Therapeutics Q2 EPS $(1.83) Misses $(1.72) Estimate, Sales $457.00K Beat $450.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
BioXcel Therapeutics reported Q2 losses of $(1.83) per share, missing the analyst consensus estimate of $(1.72) by 6.4 percent. This is a 35.56 percent decrease over losses from the same period last year. However, the company beat the sales estimate of $450.00 thousand by reporting $457.00 thousand.
August 14, 2023 | 11:03 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BioXcel Therapeutics reported a larger than expected loss for Q2, but beat sales estimates. This mixed result could lead to uncertainty in the market.
BioXcel Therapeutics reported a larger than expected loss for Q2, which is a negative signal for investors. However, the company beat sales estimates, which is a positive signal. The mixed result could lead to uncertainty in the market, making it difficult to predict the short-term price direction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100